Preferred Label : Atorvastatin;
MeSH definition : A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR
(statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL;
APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL
in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients
with multiple risk factors.; A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR
(statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL;
APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL
in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES
in patients with multiple risk factors.;
MeSH synonym : (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic
acid;
CISMeF synonym : Atorvastatin Calcium; Anhydrous, Atorvastatin Calcium; Atorvastatin Calcium Hydrate; Atorvastatin Calcium Trihydrate; Calcium Anhydrous, Atorvastatin; Calcium Hydrate, Atorvastatin; Calcium Salt Atorvastatin; Calcium Trihydrate, Atorvastatin; Calcium, Atorvastatin; Hydrate, Atorvastatin Calcium; Trihydrate, Atorvastatin Calcium;
MeSH Hyperonym : atorvastatin;
MeSH hyponym : Liptonorm; lipitor; atorvastatin calcium anhydrous; CI 981; Atorvastatin, Calcium Salt; CI-981; CI981;
MeSH Related Number : 110862-48-1; 48A5M73Z4Q; C0GEJ5QCSO; 110862-48-1 (Atorvastatin Calcium);
Registry Number MeSH : 48A5M73Z4Q;
Wikipedia link : https://en.wikipedia.org/wiki/Atorvastatin calcium;
Is substance : O;
UNII : A0JWA85V8F;
Origin ID : D000069059;
UMLS CUI : C0286651;
ATC code(s)
Allowable qualifiers
Currated CISMeF NLP mapping
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR
(statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL;
APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL
in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients
with multiple risk factors.
A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR
(statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL;
APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL
in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES
in patients with multiple risk factors.
https://www.has-sante.fr/jcms/p_3509116/fr/junaliza-atorvastatine/ezetimibe-hypolipidemiants-en-association
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
Ezetimibe
Atorvastatin
atorvastatin calcium
atorvastatin and ezetimibe
hypercholesterolemia
non-familial primary hypercholesterolemia
Familial hypercholesterolemia - heterozygous (disorder)
Mixed Hyperlipidemia
adult
evaluation of the transparency committee
drug combinations
hypolipidemic agents
---
https://www.has-sante.fr/jcms/p_3455991/fr/junaliza-atorvastatine-/-ezetimibe-hypolipidemiants-en-association
2023
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
hypercholesterolemia
adult
Primary hypercholesterolemia (disorder)
atorvastatin and ezetimibe
evaluation of the transparency committee
hypolipidemic agents
drug combinations
Atorvastatin
Ezetimibe
---
https://www.has-sante.fr/jcms/p_3217176/fr/reselip
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug combinations
Atorvastatin
Ezetimibe
hydroxymethylglutaryl-coa reductase inhibitors
atorvastatin and ezetimibe
hypercholesterolemia
Familial hypercholesterolemia - heterozygous (disorder)
Familial hypercholesterolemia - homozygous (disorder)
Primary hypercholesterolemia (disorder)
adult
mixed dyslipidemia
dyslipidemias
administration, oral
evaluation of the transparency committee
---
http://www.ansm.sante.fr/var/ansm_site/storage/original/application/2bddb5ad32111b08b86144a1d1d71caa.pdf
false
France
French
Atorvastatin
treatment outcome
antihypertensive agents
cardiovascular diseases
risk factors
amlodipine, atorvastatin drug combination
amlodipine
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
calcium channel blockers
tablets
drug combinations
atorvastatin and amlodipine
drug evaluation
Amlodipine Besylate
---
http://www.has-sante.fr/portail/jcms/c_2658564/fr/iltria
2016
false
false
false
France
French
evaluation of the transparency committee
administration, oral
drug combinations
treatment outcome
ramipril
ramipril
Atorvastatin
Atorvastatin
aspirin
aspirin
adult
secondary prevention
cardiovascular diseases
atorvastatin, acetylsalicylic acid and ramipril
hydroxymethylglutaryl-coa reductase inhibitors
angiotensin-converting enzyme inhibitors
platelet aggregation inhibitors
---
http://www.has-sante.fr/portail/jcms/c_2658564/fr/iltria-acide-acetylsalicylique/atorvastatine/ramipril-antiagregant-plaquettaire-statine-et-iec-en-association
2016
false
false
false
France
French
guidelines for drug use
evaluation of the transparency committee
administration, oral
drug combinations
treatment outcome
Atorvastatin
Atorvastatin
aspirin
aspirin
atorvastatin, acetylsalicylic acid and ramipril
ramipril
ramipril
adult
cardiovascular diseases
secondary prevention
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
angiotensin-converting enzyme inhibitors
angiotensin-converting enzyme inhibitors
platelet aggregation inhibitors
platelet aggregation inhibitors
insurance, health, reimbursement
---
http://www.has-sante.fr/portail/jcms/c_2613506/fr/tahor
2016
true
France
French
risk factors
adult
Atorvastatin
hypercholesterolemia
hydroxymethylglutaryl-coa reductase inhibitors
administration, oral
atorvastatin
insurance, health, reimbursement
cardiovascular diseases
treatment outcome
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2024177/fr/liptruzet
http://www.has-sante.fr/portail/jcms/c_2024177/fr/liptruzet-ezetimibe/atorvastatine-association-fixe-d-hypocholesterolemiants
2015
false
false
false
France
French
evaluation of the transparency committee
liptruzet
drug combinations
treatment outcome
insurance, health, reimbursement
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
adult
hypercholesterolemia
anticholesteremic agents
anticholesteremic agents
administration, oral
atorvastatin and ezetimibe
Familial hypercholesterolemia - homozygous (disorder)
guidelines for drug use
Atorvastatin
Atorvastatin
Ezetimibe
Ezetimibe
mixed dyslipidemia
---
http://www.has-sante.fr/portail/jcms/c_1769341/fr/tahor
2014
false
France
French
risk factors
adult
risk
diabetes mellitus, type 2
Atorvastatin
hydroxymethylglutaryl-coa reductase inhibitors
administration, oral
atorvastatin
insurance, health, reimbursement
cardiovascular diseases
treatment outcome
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/r_1439693
2012
true
France
French
Atorvastatin
Rosuvastatin Calcium
cardiovascular diseases
Cost-Benefit analysis
hydroxymethylglutaryl-coa reductase inhibitors
hmg coa reductase inhibitors
risk factors
cholesterol, LDL
hypercholesterolemia
simvastatin
anticholesteremic agents
pravastatin
treatment outcome
fatty acids, monounsaturated
indoles
guidelines for drug use
Fluvastatin
---
http://www.cochrane.org/fr/CD008226
2012
false
United Kingdom
France
French
Atorvastatin
Atorvastatin
review of literature
anticholesteremic agents
treatment outcome
hydroxymethylglutaryl-coa reductase inhibitors
hydroxymethylglutaryl-coa reductase inhibitors
anticholesteremic agents
dose-response relationship, drug
atorvastatin
french abstract
---
http://www.has-sante.fr/portail/jcms/c_1339956/tahor
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12516_TAHOR_21112012_AVIS_CT12516.pdf
http://www.has-sante.fr/portail/jcms/c_1007499/tahor
2012
false
France
French
Atorvastatin
administration, oral
hydroxymethylglutaryl-coa reductase inhibitors
anticholesteremic agents
atorvastatin
insurance, health, reimbursement
child
hyperlipoproteinemia type ii
hyperlipidemia, familial combined
adolescent
adult
hypercholesterolemia
evaluation of the transparency committee
---
http://www.lecrat.eu/?s=Atorvastatine
2011
false
France
French
Atorvastatin
pregnancy
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
atorvastatin
drug information
---
http://www.has-sante.fr/portail/display.jsp?id=c_522785
http://www.has-sante.fr/portail/upload/docs/application/pdf/caduet.pdf
2007
false
France
French
Atorvastatin
amlodipine
antihypertensive agents
hypertension
treatment outcome
drug combinations
atorvastatin and amlodipine
amlodipine, atorvastatin drug combination
Amlodipine Besylate
guidelines for drug use
---
http://www.has-sante.fr/portail/display.jsp?id=c_400830
2006
false
France
French
Atorvastatin
diabetes complications
hydroxymethylglutaryl-coa reductase inhibitors
tablets
administration, oral
atorvastatin
diabetes mellitus, type 2
insurance, health, reimbursement
cardiovascular diseases
treatment outcome
evaluation of the transparency committee
---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Caduet-Fr.pdf
2006
false
Canada
French
Atorvastatin
drug combinations
cardiovascular diseases
canada
antihypertensive agents
amlodipine
hypertension
hyperlipidemias
amlodipine, atorvastatin drug combination
atorvastatin and amlodipine
drug evaluation
Amlodipine Besylate
---
https://minerva-ebp.be/fr/article/805
2005
false
false
minerva-ebm.be
Belgium
French
Atorvastatin
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
intermittent claudication
exercise tolerance
treatment outcome
aged
walking
critical appraisal or critical reading
---
http://www.has-sante.fr/portail/display.jsp?id=c_400768
2005
false
France
French
Atorvastatin
atorvastatin and amlodipine
drug combinations
amlodipine, atorvastatin drug combination
amlodipine
antihypertensive agents
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
calcium channel blockers
tablets
administration, oral
hypertension
cardiovascular diseases
risk factors
insurance, health, reimbursement
evaluation of the transparency committee
Amlodipine Besylate
---